logo
logo

LUCA Science Announces $9.8 Million Series A Financing to Support Research and Development of Functional Mitochondria as Therapeutic Agents

Sep 01, 2020•about 5 years ago

Amount Raised

$9 Million

Round Type

series a

Description

LUCA Science, a company developing functional mitochondria as therapeutic agents, an emerging platform to treat damaged tissues and organs, today announced the closing of a $9.8 million Series A financing. The funding round was led by Axil Capital Partners. Additional participating investors included Remiges Ventures, Nippon Venture Capital, Fast Track Initiative and CaHC.

Company Information

Company

Luca Science

About

Philippe Fauchet, OBE, Venture Partner at 4BIO Capital, said: “LUCA Science has all the right ingredients to be an international success: it has the science, international team, and fantastic support from experienced investors. LUCA Science will use its platform technology to manufacture, store and deliver innovative mitochondrial drugs to research and development of therapeutics for unmet medical needs in a wide range of diseases for which there have been no effective treatments. LUCA Science is a preclinical stage biopharmaceutical company pioneering a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs.

Related People